Key facts

Norgine fact sheet

 

We are a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, we generated €368M total revenue and income.  

We employ over 1,000 people across our commercial, development and manufacturing operations. We manage all aspects of product development, production, marketing, sales and supply. 

Our approach and infrastructure is integrated and focused on ensuring that we win and deliver upon partnership opportunities for growth.

Our locations

 

We are headquartered in the Netherlands and own an R&D site in Hengoed, Wales and two manufacturing sites, in Hengoed, Wales and in Dreux, France.

Overall, we have sites and offices in the UK (Harefield and Hengoed), France (Rueil and Dreux), Germany (Marburg), Belgium (Heverlee), The Netherlands (Amsterdam), Nordics (Copenhagen), Switzerland (Muttenz), Austria (Vienna), Italy (Milan), Portugal (Lisbon) and Spain (Madrid). Outside Europe, we have offices in Australia and New Zealand (Sydney).

Our employees

 

We employ over 1,000 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe, Australia and New Zealand.

 

2016 performance

 

Total revenue and income*

*total revenue and income consist of product sales, partnering milestones and other income

 

 

Product sales

Down 2% from 2015 due to currency and disposals

Underlying growth up by 6.8%* driven by XIFAXAN®

 

Key partnering milestones

 

Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare and the lives of patients and their carers.

  • Norgine entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra
    March 2017
  • Norgine enters co-promotion agreement with Pfizer in Germany for INFLECTRA® (infliximab) for the treatment of Crohn’s disease and ulcerative colitis
    September 2016
  • Norgine licensed out NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada
    August 2016
  • Norgine divests its MENA operations and product rights to Acino
    June 2016
  • Norgine expands its partnership with A Pharm s.r.l. to distribute ZIVEREL® in Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the UK
    April 2016